GlaxoSmithKline files for a potential blockbuster shingles vax. On Monday, Glaxo filed its experimental shingles vaccine Shingrix for FDA clearance, setting up what could become the first major approval of incoming CEO Emma Walmsley's tenure as chief executive. The vax has shown solid results in clinical trials and that could give it a big leg up on Merck's rival Zostavax, potentially bringing GSK $1 billion per year in sales if Shingrix crosses the regulatory finish line. ( Fortune )